Evolent Health Inc. (NYSE:EVH) received a $31.00 price target from equities researchers at Canaccord Genuity in a report released on Tuesday. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s price target points to a potential upside of 47.62% from the company’s previous close.

Other equities analysts have also issued reports about the company. Jefferies Group started coverage on Evolent Health in a research report on Tuesday, July 26th. They set a “buy” rating and a $28.00 price target on the stock. FBR & Co boosted their price target on Evolent Health from $24.00 to $26.00 and gave the stock an “outperform” rating in a research report on Friday, August 5th. William Blair reissued an “outperform” rating on shares of Evolent Health in a research report on Friday, September 30th. Leerink Swann reissued a “buy” rating on shares of Evolent Health in a research report on Wednesday, October 5th. Finally, Zacks Investment Research lowered Evolent Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $27.83.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Evolent Health (NYSE:EVH) opened at 21.00 on Tuesday. Evolent Health has a 12 month low of $8.14 and a 12 month high of $26.84. The stock’s 50 day moving average is $21.39 and its 200-day moving average is $20.71. The stock’s market capitalization is $1.43 billion.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Wednesday, November 9th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The business had revenue of $60.20 million for the quarter, compared to analyst estimates of $58.35 million. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. The company’s revenue was up 39.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.16) EPS. On average, equities research analysts expect that Evolent Health will post ($0.57) earnings per share for the current year.

In other news, COO Thomas Peterson III sold 72,827 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $21.54, for a total value of $1,568,693.58. Following the completion of the sale, the chief operating officer now directly owns 377,623 shares in the company, valued at approximately $8,133,999.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael D’amato purchased 10,000 shares of the stock in a transaction dated Monday, November 14th. The stock was purchased at an average price of $17.18 per share, with a total value of $171,800.00. Following the completion of the acquisition, the director now directly owns 18,183 shares in the company, valued at approximately $312,383.94. The disclosure for this purchase can be found here. 8.85% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Credit Suisse AG increased its stake in shares of Evolent Health by 99.9% in the third quarter. Credit Suisse AG now owns 38,420 shares of the company’s stock worth $945,000 after buying an additional 19,204 shares during the period. Panagora Asset Management Inc. purchased a new stake in shares of Evolent Health during the third quarter worth $4,555,000. Capital World Investors increased its stake in shares of Evolent Health by 749.7% in the third quarter. Capital World Investors now owns 1,370,000 shares of the company’s stock worth $33,729,000 after buying an additional 1,208,762 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Evolent Health during the third quarter worth $280,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Evolent Health during the third quarter worth $1,672,000. Institutional investors and hedge funds own 37.14% of the company’s stock.

WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/24/evolent-health-inc-evh-pt-set-at-31-00-by-canaccord-genuity.html.

About Evolent Health

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Stock Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related stocks with our FREE daily email newsletter.